MTX monotherapy users (n = 741) | Multiple nbDMARD users (n = 995) | |
---|---|---|
Patient factors | ||
High disease activity (vs. moderateb) | 1.85 (1.29–2.66) | 1.67 (1.23–2.26) |
Disease duration (per 5 years) | 0.95 (0.87–1.05) | 0.85 (0.79–0.91) |
Provider factors | ||
Geographic region | ||
Northeast (reference) | 1 | 1 |
South | 1.14 (0.63–2.07) | 1.23 (0.86–1.77) |
Midwest | 1.56 (0.82–2.97) | 1.67 (1.18–2.37) |
West | 1.92 (0.83–4.42) | 1.06 (0.61–1.82) |
Time period | ||
December 2008–November 2009 (reference) | 1 | 1 |
December 2009–November 2010 | 0.81 (0.52–1.28) | 1.15 (0.82–1.62) |
December 2010–November 2011 | 1.09 (0.70–1.71) | 0.86 (0.59–1.26) |
December 2011–February 2013 | 0.71 (0.42–1.19) | 0.76 (0.50–1.14) |